Lung cancer remains a severe malignancy, expected to account for over 125,000 deaths in 2024.  With high rates of mortality ...

A study of patients with metastatic lung cancer by researchers based in Brazil and the United States has found that their ...

A new case report was published in Oncoscience (Volume 11) on October 8, 2024, entitled, “Complete and long-lasting response ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...

In the last decade, immunotherapy agents changed the treatment landscape for Non-Small Cell Lung Cancer (NSCLC)."BUFFALO, NY ...

Genelux Corporation (NASDAQ: GNLX), a late-stage clinical immuno-oncology company, today announced that the first patient has been dosed in the U.S.-based Phase 2 (VIRO-25) trial evaluating ...

In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...

The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell ...

Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may ...

An expert discussed how the understanding of resistance mechanisms can help care teams develop a global treatment strategy ...

Breast cancer is the number one cancer among women: more than 2 million cases were diagnosed worldwide in 2022. It is also ...